Katherine K Matthay

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study
    Katherine K Matthay
    University of California School of Medicine, 505 Parnassus Ave, Room M647, San Francisco, CA, 94143 0106, USA
    J Clin Oncol 27:1007-13. 2009
  2. doi request reprint Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption
    Katherine K Matthay
    Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, CA 94143, USA
    Clin Cancer Res 19:311-3. 2013
  3. doi request reprint Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial
    Katherine K Matthay
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    J Nucl Med 53:1155-63. 2012
  4. pmc Promising therapeutic targets in neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF Benioff Children s Hospital, UCSF Medical Center, University of California, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 18:2740-53. 2012
  5. ncbi request reprint Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 24:500-6. 2006
  6. ncbi request reprint Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, University of California at San Francisco, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 25:1054-60. 2007
  7. pmc Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, 505 Parnassus, M647, San Francisco, CA 94143 0106, USA
    J Clin Oncol 27:1020-5. 2009
  8. pmc Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
    K K Matthay
    Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Br J Cancer 102:1319-26. 2010
  9. ncbi request reprint Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma
    Brian Weiss
    Department of Pediatrics, M647, University of California San Francisco, 505 Parnassus, San Francisco, CA 94143 0106, USA
    J Pediatr Hematol Oncol 25:543-7. 2003
  10. ncbi request reprint Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients
    Katherine K Matthay
    Department of Pediatrics, University of California San Francisco, San Francisco, California 94143, USA
    Cancer 98:155-65. 2003

Research Grants

  1. CHILDRENS CANCER GROUP
    Katherine Matthay; Fiscal Year: 2002
  2. 131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*
    Katherine Matthay; Fiscal Year: 2004

Detail Information

Publications77

  1. pmc Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study
    Katherine K Matthay
    University of California School of Medicine, 505 Parnassus Ave, Room M647, San Francisco, CA, 94143 0106, USA
    J Clin Oncol 27:1007-13. 2009
    ....
  2. doi request reprint Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption
    Katherine K Matthay
    Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, CA 94143, USA
    Clin Cancer Res 19:311-3. 2013
    ..Pharmacokinetics of isotretinoin may be negatively affected by the mode of drug administration and the dosing formula...
  3. doi request reprint Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial
    Katherine K Matthay
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    J Nucl Med 53:1155-63. 2012
    ..Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-MIBG, with secondary aims of assessing tumor and organ dosimetry and overall response...
  4. pmc Promising therapeutic targets in neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF Benioff Children s Hospital, UCSF Medical Center, University of California, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 18:2740-53. 2012
    ..Further clinical development of targeted treatments offers new hope for children with neuroblastoma...
  5. ncbi request reprint Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 24:500-6. 2006
    ..To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma...
  6. ncbi request reprint Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, University of California at San Francisco, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 25:1054-60. 2007
    ..To evaluate the effect of disease sites and prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patients with resistant neuroblastoma...
  7. pmc Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, 505 Parnassus, M647, San Francisco, CA 94143 0106, USA
    J Clin Oncol 27:1020-5. 2009
    ..The goal was to determine the maximum-tolerated dose of (131)I-MIBG in two consecutive infusions at a 2-week interval, supported by autologous stem-cell rescue (ASCR) 2 weeks after the second dose...
  8. pmc Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
    K K Matthay
    Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Br J Cancer 102:1319-26. 2010
    ..The goal of this report was to develop consensus guidelines for the use of mIBG scans in staging, response assessment and surveillance in neuroblastoma...
  9. ncbi request reprint Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma
    Brian Weiss
    Department of Pediatrics, M647, University of California San Francisco, 505 Parnassus, San Francisco, CA 94143 0106, USA
    J Pediatr Hematol Oncol 25:543-7. 2003
    ..To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for neuroblastoma...
  10. ncbi request reprint Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients
    Katherine K Matthay
    Department of Pediatrics, University of California San Francisco, San Francisco, California 94143, USA
    Cancer 98:155-65. 2003
    ..Further definition of the radiologic, clinical, and biologic features may provide clues to the predisposing factors and mechanisms of CNS dissemination...
  11. ncbi request reprint Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, University of California School of Medicine, San Francisco 94143 0106, USA
    J Clin Oncol 21:2486-91. 2003
    ..The aim of this study was to correlate early response to therapy by MIBG scan, using a semiquantitative scoring method, with the end induction response and event-free survival (EFS) rate in stage IV neuroblastoma...
  12. pmc Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group
    Julie R Park
    Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
    Pediatr Blood Cancer 52:44-50. 2009
    ..The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial...
  13. pmc Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma
    Sara Gonias
    Department of Pediatrics, University of California, San Francisco, 350 Parnassus Ave, Suite 710, San Francisco, CA 94117, USA
    J Clin Oncol 27:4162-8. 2009
    ..To evaluate the safety and efficacy of high-dose [(131)I]metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL)...
  14. pmc Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
    Denah R Taggart
    UCSF School of Medicine and Benioff Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 29:4358-64. 2011
    ..Our aim was to determine which prognostic features could be used for optimal risk classification among patients younger than 18 months with metastatic disease...
  15. ncbi request reprint Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma
    James P Howard
    Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Children s Hospital, San Francisco, California, USA
    Pediatr Blood Cancer 44:232-9. 2005
    ..Toxicity is mainly limited to myelosuppression. The aim of this study was to determine the response rate and hematologic toxicity of multiple infusions of (131)I-MIBG...
  16. ncbi request reprint Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 22:2452-60. 2004
    ..The goal of this study was to determine risk factors for myelosuppression and the need for AHSCT after (131)I-MIBG treatment...
  17. ncbi request reprint Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study
    Mary Lou Schmidt
    Department of Pediatrics, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA
    J Clin Oncol 23:6474-80. 2005
    ..The long-term survival of children between age 12 and 24 months with stage 4 neuroblastoma and nonamplified MYCN (MYCN-NA) has not been defined previously...
  18. ncbi request reprint Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study
    Daphne A Haas-Kogan
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 56:28-39. 2003
    ..To assess the effect of local radiation administered to primary disease sites in children with high-risk neuroblastoma...
  19. doi request reprint Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
    Gregory A Yanik
    Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Nucl Med 54:541-8. 2013
    ..A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with high-risk metastatic disease...
  20. pmc Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model
    Youngho Seo
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
    Mol Imaging Biol 14:735-42. 2012
    ....
  21. ncbi request reprint Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
    Julia A Messina
    Department of Pediatrics, University of California, San Francisco, California 94143, USA
    Pediatr Blood Cancer 47:865-74. 2006
    ..The purpose of this study was to determine the accuracy of two semi-quantitative scoring systems to assess response to (131)I-metaiodobenzylguanidine (mIBG) therapy in recurrent neuroblastoma...
  22. pmc The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report
    Susan L Cohn
    Department of Pediatrics, The University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 27:289-97. 2009
    ..The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification...
  23. pmc Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
    Alice L Yu
    University of California, San Diego, and Moores Cancer Center, San Diego, CA 92103 8447, USA
    N Engl J Med 363:1324-34. 2010
    ..We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma...
  24. pmc Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma
    Yvan H Chanthery
    Biomedical Science Graduate Program, University of California, San Francisco, 1450 Third Street, MC0520, San Francisco, CA 94158 9001, USA
    Sci Transl Med 4:115ra3. 2012
    ..Our data demonstrated significantly improved survival in treated animals and suggest that NVP-BEZ235 should be tested in children with high-risk, MYCN-amplified neuroblastoma...
  25. pmc Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction
    Louis Chesler
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    Neoplasia 10:1268-74. 2008
    ....
  26. pmc Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma
    Alekist Quach
    Department of Pediatrics, UCSF Children s Hospital, University of California, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 56:191-201. 2011
    ..The aim of our study was to analyze the effects of (131) I-MIBG therapy on thyroid and liver function...
  27. pmc Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma
    Jeremy M Sharib
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 59:611-6. 2012
    ..Patients with ES are treated with intensive chemotherapy regimens. We describe predictors of acute chemotherapy-associated toxicity in this population...
  28. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
    ..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
  29. pmc Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy
    Christina Baggott
    Department of Physiological Nursing and Office of Research, School of Nursing, University of California San Francisco, 2 Koret Way, San Francisco, CA 94143 0610, USA
    Cancer Nurs 35:19-28. 2012
    ..The ability to identify symptom clusters that are specific to pediatric oncology patients may lead to improved understanding of symptoms' underlying mechanisms among patients of all ages...
  30. pmc An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy
    Christina R Baggott
    Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA 94143, USA
    Support Care Cancer 19:353-61. 2011
    ....
  31. ncbi request reprint Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)
    Paul A Fitzgerald
    Department of Medicine, UCSF Comprehensive Cancer Center, Box 1222, University of California, San Francisco, San Francisco, CA 94143 1222, USA
    Ann N Y Acad Sci 1073:465-90. 2006
    ..For patients with metastatic PHEO or PGL, who have good *I-MIBG uptake on diagnostic scanning, high-dose 131I-MIBG therapy was effective in producing a sustained CR, PR, or SD in 67% of patients, with tolerable toxicity...
  32. pmc Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
    Cancer Lett 306:223-9. 2011
    ..DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86...
  33. pmc Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis
    Erin E Karski
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA 94143 0106, USA
    Cancer Epidemiol 37:29-33. 2013
    ..The peak incidence of Ewing sarcoma (EWS) is in adolescence, with little known about patients who are ≥40 years at diagnosis. We describe the clinical characteristics and survival of this rare group...
  34. pmc Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems
    Swati S More
    Departments of Bioengineering and Therapeutic Sciences, UCSF School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California 94158, USA
    Clin Cancer Res 17:2339-49. 2011
    ....
  35. pmc Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults
    Alexei L Polishchuk
    Department of Pediatrics, University of California at San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California, USA
    Cancer 117:4286-93. 2011
    ..The objective of the current study was to characterize the toxicity and activity of this therapy in older patients...
  36. pmc Osteosarcoma in children 5 years of age or younger at initial diagnosis
    Jennifer Worch
    Department of Pediatrics and Department of Epidemiology Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA
    Pediatr Blood Cancer 55:285-9. 2010
    ..Since osteosarcoma is extremely rare in children < or =5 years of age, we sought to investigate if tumor characteristics, treatment strategies, and outcomes differ compared to older patients...
  37. doi request reprint Adverse impact of regional lymph node involvement in osteosarcoma
    Sheila Thampi
    Department of Pediatrics, University of California, San Francisco School of Medicine, 505 Parnassus Ave, San Francisco, CA 94143, United States
    Eur J Cancer 49:3471-6. 2013
    ..We investigated incidence, patient characteristics and survival for patients with osteosarcoma and regional lymph node involvement at diagnosis...
  38. pmc Clinical features and outcomes in patients with extraskeletal Ewing sarcoma
    Mark A Applebaum
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California, USA
    Cancer 117:3027-32. 2011
    ..The purpose of this study was to investigate whether patient characteristics, treatment strategies, and outcomes differ between skeletal Ewing sarcoma and extraskeletal Ewing sarcoma (EES)...
  39. doi request reprint Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy
    Siavash Jabbari
    Department of Radiation Oncology, University of California, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 75:177-82. 2009
    ..To evaluate the role of radiation therapy (RT) as a component of multimodality therapy for pediatric desmoids...
  40. pmc Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 675 Nelson Ring, Sandler Neuroscience Center, UCSF, San Francisco, CA 94148, USA
    Anticancer Res 33:755-62. 2013
    ..To assess poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 together with radiation for the treatment of neuroblastoma...
  41. pmc Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma
    Denah R Taggart
    Department of Pediatrics and Nuclear Medicine, University of California, San Francisco, CA 94143 0106, USA
    J Clin Oncol 27:5343-9. 2009
    ....
  42. ncbi request reprint The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma
    Araz Marachelian
    Department of Pediatrics, Children s Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, USA
    Pediatr Blood Cancer 58:675-81. 2012
    ..To describe the serial histopathology of intermediate risk stage 3 neuroblastoma after chemotherapy, and correlate with residual mass at therapy completion and outcome...
  43. doi request reprint Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG)
    Thalia Wong
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 60:1424-30. 2013
    ..The aim of our study was to evaluate systematically the acute effects of (131)I-MIBG on blood pressure in patients with neuroblastoma and to identify possible predictors of hypertension...
  44. pmc Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, California, USA
    Pediatr Blood Cancer 51:589-92. 2008
    ..We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international database...
  45. pmc Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 59:52-6. 2012
    ..Ewing sarcoma is a malignant bone tumor characterized by a high frequency of somatic EWSR1 translocations. Ewing sarcoma is less common in people of African or African-American ancestry, suggesting a genetic etiology...
  46. doi request reprint Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy
    Christina Baggott
    University of California San Francisco, San Francisco, CA 94143, USA
    J Pediatr Oncol Nurs 27:307-15. 2010
    ..No significant differences over time were found in any of the symptom severity scores on the MSAS. Children experienced a high number of symptoms at the initiation of a chemotherapy cycle that persisted over the subsequent 2 weeks...
  47. pmc Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation
    Jennifer Worch
    Department of Pediatrics, University of California, San Francisco, School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Epidemiol Biomarkers Prev 20:449-53. 2011
    ..The incidence of Ewing sarcoma varies by race, with very low rates among persons of African and East Asian ancestry. The incidence by race of other mesenchymal tumors that also harbor EWSR1 translocations has not been studied...
  48. pmc Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, Box 0106, San Francisco, CA 94143 0106, USA
    Nucl Med Biol 35:S35-48. 2008
    ..Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use of radiolabeled MIBG for targeted radiotherapy in these tumors...
  49. ncbi request reprint Neuroblastoma: biology and staging
    Sabine Mueller
    Department of Pediatric Hematology Oncology, University of California, San Francisco School of Medicine, M647, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Curr Oncol Rep 11:431-8. 2009
    ..This review discusses the biology of these tumors, current and new risk classification, and staging recommendations, with a brief outline of preferred treatment strategies...
  50. ncbi request reprint Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma
    Amy M Gillis
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94115 1708, USA
    Int J Radiat Oncol Biol Phys 69:858-64. 2007
    ..To review a historical cohort of consecutively accrued patients with high-risk neuroblastoma treated with intraoperative radiotherapy (IORT) to determine the therapeutic effect and late complications of this treatment...
  51. pmc Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET
    Chang Lae Lee
    Department of Radiology and Biomedical Imaging, UCSF Physics Research Laboratory, University of California, San Francisco, San Francisco, California 94143, USA
    Med Phys 37:4861-7. 2010
    ..The aim of this work was to estimate human-equivalent internal radiation dose of 124I-MIBG using PET/CT data in a murine xenograft model...
  52. ncbi request reprint Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group
    James G Gurney
    Department of Pediatrics, University of Michigan, 300 N Ingalls St, Room 6E02, Ann Arbor, MI 48109, USA
    Pediatrics 120:e1229-36. 2007
    ....
  53. ncbi request reprint Is liver metastasis in neuroblastoma an indication for treatment reduction?
    Katherine K Matthay
    University of California San Francisco and UCSF Children s Hospital, 94143 0106, USA
    Pediatr Blood Cancer 46:269-70. 2006
  54. pmc Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow
    Steven G DuBois
    Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Pediatr Blood Cancer 54:13-8. 2010
    ..A new method for detecting circulating Ewing sarcoma cells using flow cytometry is described. This strategy exploits the nearly universal expression of CD99 and the lack of expression of CD45 by Ewing sarcoma cells...
  55. pmc Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells
    Gary E Meyer
    Department of Pediatrics, University of California, San Francisco, California 94143, USA
    J Cell Biochem 102:1529-41. 2007
    ..In addition, NDGA inhibits the growth of xenografted human neuroblastoma tumors in nude mice. These results indicate that NDGA may be useful in the treatment of neuroblastoma and may function in part via disruption of IGF-IR signaling...
  56. doi request reprint Current treatment and outcome for childhood acute leukemia in Tanzania
    Elizabeth Kersten
    Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California
    Pediatr Blood Cancer 60:2047-53. 2013
    ....
  57. doi request reprint Infections in hospitalized children and young adults with acute leukemia in Morocco
    Jacqueline Depasse
    Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, CA 94143 0106, USA
    Pediatr Blood Cancer 60:916-22. 2013
    ..Our purpose was to describe the incidence, clinical features, and mortality of febrile illness with or without documented infection in children and young adults treated for AML and ALL in two centers in Rabat and Casablanca during 2011...
  58. pmc Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
    Louis Chesler
    Department of Neurology, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA
    Cancer Res 66:8139-46. 2006
    ....
  59. pmc Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M696, San Francisco, CA 94143 0106, USA
    Int J Mol Imaging 2012:250834. 2012
    ..0002). Conclusions. NET protein expression in neuroblastoma correlates with MIBG avidity. MYCN amplified tumors have lower NET protein expression...
  60. doi request reprint Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma
    William Clay Gustafson
    Department of Pediatrics, University of California School of Medicine, San Francisco, CA, USA
    Expert Rev Neurother 11:1411-23. 2011
    ..Current investigations focus on overcoming resistance by elucidating the molecular/genetic causes of neuroblastoma tumorigenesis and progression, with the aim of developing more effective biologically targeted therapies for this disease...
  61. pmc Ethnic and racial differences in patients with Ewing sarcoma
    Jennifer Worch
    Department of Pediatrics, University of California at San Francisco School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer 116:983-8. 2010
    ..The goal of the current study was to evaluate racial and ethnic differences in presentation and overall survival (OS) among patients diagnosed with ES before age 40 years...
  62. ncbi request reprint High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
    Brian Rose
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Cancer 98:239-48. 2003
    ..The authors reported the response rates and toxicity levels in patients with malignant pheochromocytoma or paraganglioma who were treated with high-dose 131I-MIBG...
  63. ncbi request reprint Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Cancer Lett 228:275-82. 2005
    ....
  64. ncbi request reprint Neuroblastoma: evolving therapies for a disease with many faces
    Robert E Goldsby
    Division of Pediatric Hematology Oncology, University of California, San Francisco 94143 0106, USA
    Paediatr Drugs 6:107-22. 2004
    ..Research efforts to understand the biologic basis of neuroblastoma and to identify new, more effective therapies are essential to improve the outcome for these children...
  65. ncbi request reprint Chemotherapy for neuroblastoma: does it hit the target?
    Katherine K Matthay
    Lancet Oncol 9:195-6. 2008
  66. ncbi request reprint Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study
    E Stanton Adkins
    J Pediatr Surg 39:931-6. 2004
    ..The authors evaluated the effect of complete primary site resection on event-free survival (EFS), overall survival (OS), and complication rates in patients entered on a high-risk neuroblastoma treatment protocol...
  67. ncbi request reprint Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma
    Gregory A Yanik
    Blood and Marrow Stem Cell Transplantation Program, Division of Pediatric Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Clin Oncol 20:2142-9. 2002
    ..A pilot study was performed to examine the feasibility of a novel regimen combining (131)I-MIBG and myeloablative chemotherapy with autologous stem-cell rescue...
  68. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
    ..Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors...
  69. ncbi request reprint Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA 19104 4318, USA
    N Engl J Med 353:2243-53. 2005
    ..Neuroblastoma is a childhood cancer with considerable morbidity and mortality. Tumor-derived biomarkers may improve risk stratification...
  70. ncbi request reprint TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance
    Hiroyuki Shimada
    Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California 90027, USA
    Cancer 101:1873-81. 2004
    ..This study was conducted to investigate the prognostic significance and biologic relevance of trkA expression levels in peripheral neuroblastic tumors (pNTs) (i.e., neuroblastoma, ganglioneuroblastoma, and ganglioneuroma)...
  71. ncbi request reprint Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index
    Chie Kobayashi
    Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
    Cancer 103:174-80. 2005
    ..Nonetheless, certain tumors possessing these histologic characteristics contain a nonamplified MYCN gene (NA-MYCN)...
  72. ncbi request reprint International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age
    Hideki Sano
    Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, and Keck School of Medicine, University of Southern California, 4650 Sunset Blvd M S 43, Los Angeles, CA 90027, United States
    Eur J Cancer 42:1113-9. 2006
    ..Due to the fact that INPC incorporated age factor (18, 60 months) in the system, it served better than age by itself for prognostic distinction of pNT patients...
  73. ncbi request reprint Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number
    Qun Wang
    Division of Oncology, Children s Hospital of Philadelphia, PA 19104 4399, USA
    Cancer Res 66:6050-62. 2006
    ..Lead positional candidates for neuroblastoma suppressor genes can be inferred from these data, but the potential multiplicity of transcripts involved has significant implications for ongoing gene discovery strategies...
  74. ncbi request reprint A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study
    Peter C Adamson
    The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pediatr Blood Cancer 49:661-5. 2007
    ....
  75. ncbi request reprint The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
    Wendy B London
    University of Florida and Children s Oncology Group Department of Statistics, 104 N Main St, 600, Gainesville, FL 32601, USA
    Cancer Lett 228:257-66. 2005
    ..However, Italian results in INSS stage 4 patients show that outcome in patients 12-17 months is not better than that of older patients. Further analyses are warrented...
  76. ncbi request reprint Retinoid therapy of high-risk neuroblastoma
    C Patrick Reynolds
    Division of Hematology Oncology, Children s Hospital of Los Angeles and the University of Southern California Keck School of Medicine, Los Angeles, CA 90054, USA
    Cancer Lett 197:185-92. 2003
    ..Thus, further clinical trials of 4-HPR in neuroblastoma, and of 4-HPR in combination with ceramide modulators, are warranted...
  77. ncbi request reprint Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular
    Michel Peuchmaur
    Service de Pathologie, Hopital Robert Debre, Paris, France
    Cancer 98:2274-81. 2003
    ..Subsequently, it has been reported that GNBn can be divided into two prognostic subsets, a favorable subset (FS) and an unfavorable subset (US)...

Research Grants2

  1. CHILDRENS CANCER GROUP
    Katherine Matthay; Fiscal Year: 2002
    ..Our strong biology research laboratories in brain tumors, neuroblastoma and myeloproliferative disorders are conducting multiple biology studies in the Group and providing new information for future studies. ..
  2. 131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*
    Katherine Matthay; Fiscal Year: 2004
    ..Significance: The higher tumor-specific radiation doses possible with this protocol may provide a treatment to improve response and survival in children with resistant neuroblastoma. ..